199 related articles for article (PubMed ID: 26048096)
21. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
[TBL] [Abstract][Full Text] [Related]
22. Brigatinib pharmacokinetics in patients with chronic hepatic impairment.
Hanley MJ; Kerstein D; Tugnait M; Narasimhan N; Marbury TC; Venkatakrishnan K; Gupta N
Invest New Drugs; 2023 Jun; 41(3):402-410. PubMed ID: 37052729
[TBL] [Abstract][Full Text] [Related]
23. Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Oral Ivosidenib in Otherwise Healthy Participants.
Fan B; Dai D; Cohen M; Xu H; Yin F; Nagaraja R; Mobilia M; Almon C; Basile FG; Yang H
Clin Pharmacol Drug Dev; 2021 Jan; 10(1):99-109. PubMed ID: 32648303
[TBL] [Abstract][Full Text] [Related]
24. Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration.
Shumaker R; Aluri J; Fan J; Martinez G; Pentikis H; Ren M
J Clin Pharmacol; 2015 Mar; 55(3):317-27. PubMed ID: 25204557
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A
Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.
Martin P; Oliver S; Gillen M; Marbury T; Millson D
Clin Ther; 2015 Dec; 37(12):2823-36. PubMed ID: 26519231
[TBL] [Abstract][Full Text] [Related]
27. A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects.
Krauwinkel W; Noukens J; van Dijk J; Popa S; Ouatas T; de Vries M; Phung D; Gibbons J; Mordenti J; Mateva L
J Clin Pharm Ther; 2017 Jun; 42(3):268-275. PubMed ID: 28251667
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects.
Dymond AW; Martin P; So K; Huang Y; Severin P; Holmes V; Mariani G; Marbury T
J Clin Pharmacol; 2017 May; 57(5):592-605. PubMed ID: 28019010
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study.
Lasseter KC; Dilzer SC; Vargas R; Waldman S; Noveck RJ
Clin Pharmacokinet; 2004; 43(2):121-9. PubMed ID: 14748620
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
[TBL] [Abstract][Full Text] [Related]
32. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.
Peveling-Oberhag J; Zeuzem S; Yong WP; Kunz T; Paquet T; Bouillaud E; Urva S; Anak O; Sellami D; Kobalava Z
Clin Ther; 2013 Mar; 35(3):215-25. PubMed ID: 23453404
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment.
van Herpen CM; Lassen U; Desar IM; Brown KH; Marotti M; de Jonge MJ
Anticancer Drugs; 2013 Feb; 24(2):204-11. PubMed ID: 23197081
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction.
Zhou X; Lockhart AC; Fu S; Nemunaitis J; Sarantopoulos J; Muehler A; Rangachari L; Bargfrede M; Venkatakrishnan K
J Clin Pharmacol; 2019 Sep; 59(9):1204-1215. PubMed ID: 30985952
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of sunitinib malate in subjects with hepatic impairment.
Bello CL; Garrett M; Sherman L; Smeraglia J; Ryan B; Toh M
Cancer Chemother Pharmacol; 2010 Sep; 66(4):699-707. PubMed ID: 20049443
[TBL] [Abstract][Full Text] [Related]
36. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.
Peters S; Zimmermann S; Adjei AA
Cancer Treat Rev; 2014 Sep; 40(8):917-26. PubMed ID: 25027951
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment.
de Zeeuw D; Remuzzi G; Kirch W
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S37-42. PubMed ID: 9331004
[TBL] [Abstract][Full Text] [Related]
38. Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers.
Ruiz-Garcia A; Masters JC; Mendes da Costa L; LaBadie RR; Liang Y; Ni G; Ellery CA; Boutros T; Goldberg Z; Bello CL
J Clin Pharmacol; 2016 Feb; 56(2):223-30. PubMed ID: 26179237
[TBL] [Abstract][Full Text] [Related]
39. Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics.
Cheeti S; Deng Y; Chang I; Georgescu I; Templeton I; Choong N; Cheung KWK; Girish S; Musib L
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):144-152. PubMed ID: 32696585
[TBL] [Abstract][Full Text] [Related]
40. Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib.
Morcos PN; Cleary Y; Sturm-Pellanda C; Guerini E; Abt M; Donzelli M; Vazvaei F; Balas B; Parrott N; Yu L
J Clin Pharmacol; 2018 Dec; 58(12):1618-1628. PubMed ID: 30052269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]